This content is machine translated Follicular lymphoma Addition of tafasitamab significantly improves progression-free survival The results of the phase 3 study (inMIND) indicate a new treatment option for relapsed or refractory follicular lymphoma: The addition of tafasitamab to lenalidomide and rituximab significantly prolonged progression-free...…
View Post 3 min This content is machine translated Follicular lymphoma Rituximab in maintenance monotherapy. A study presented at ASH 2013 in New Orleans examined the role of rituximab in maintenance therapy in patients with follicular lymphoma. The study showed that the drug, when applied…
View Post 6 min This content is machine translated Chronic lymphocytic leukemia and non-Hodgkin's lymphoma Updates on the active ingredients GA101 and rituximab Three studies on chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma were discussed at the ASH in New Orleans: One was an update on the stage 1 analysis of the CLL11…
